BioAtla Faces Nasdaq Delisting Over Listing Rule Violations

Reuters
02/07
BioAtla Faces Nasdaq Delisting Over Listing Rule Violations

BioAtla Inc. is facing a significant regulatory issue after receiving notice from Nasdaq that its securities will be suspended from trading due to non-compliance with the $1.00 minimum bid price requirement and the $2.5 million stockholders' equity requirement. The company had previously met an alternative market value standard but failed to maintain compliance. BioAtla is appealing the delisting determination to the Nasdaq Listing Council, but trading on Nasdaq may be suspended while the appeal is pending. If delisted, BioAtla’s stock is expected to move to the OTCID market, which could negatively affect trading price and volume, and there is no assurance a market for its shares will be maintained.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioAtla Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-041367), on February 06, 2026, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10